How Multi-omics Analysis and AI-driven Drug Design Can Accelerate Early Drug Discovery

One of the key areas for optimization in the drug development process is the discovery stage. Traditional methods are time-consuming and often produce leads that ultimately fail.

In this webinar, Dr. Brett Pickett, Assistant Professor at BYU and co-founder of Pythia Bio, and Dr. Jeremy Jones, Principal Scientist of AI-driven Drug Design (AIDD) at Simulations Plus, will discuss how comprehensive multi-omics analyses can be paired with AIDD to identify novel disease targets and rapidly develop leads for that target. They’ll also cover how to identify additional indications for existing drug candidates to strengthen their likelihood of success.